Nvidia's (NASDAQ: NVDA) share price rallied 4.9% on Tuesday after Swiss investment bank UBS named the chipmaker one of its top stock picks for the year ahead. UBS analyst Timothy Arcuri believes Nvidia is building a wide competitive moat around its business. After a steep decline from its highs in November, Nvidia's stock price recovered some of its recent losses on Tuesday. Read More...
Motley Fool
Better Buy: Viatris vs. AbbVie
With a market cap of nearly $16 billion, the generic drugmaker Viatris (NASDAQ: VTRS) is minuscule in comparison to the profitable pharma titan AbbVie’s (NYSE: ABBV) $228 billion. Viatris owns the rights to manufacture money-printing drugs like Lipitor, Lyrica, Xanax, Viagra, and Zoloft, all of which are available as generics. Because the demand for generic drugs is largely predictable, it hopes to pay out an ever-increasing dividend to its shareholders using stable cash flows.
